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a  b  s  t  r  a  c  t
This study  reports  on the detailed  investigation  of human  deoxynivalenol  (DON)  and  zearalenone  (ZEN)
in  vivo  metabolism  through  the  analysis  of  urine  samples  obtained  from  one  volunteer  following  a nat-
urally  contaminated  diet  containing  138 g DON and  10 g ZEN  over  a period  of  four  days.  Based  on
the  mycotoxin  intake  and the  concentrations  of  mycotoxin  conjugates  in  urine,  a mass  balance  was
established.  The  average  rates  of  DON  excretion  and  glucuronidation  were  determined  to be  68  and
76%,  respectively.  The  investigation  of  formed  glucuronides  revealed  DON-15-glucuronide  as main  con-
jugation  product  besides  DON-3-glucuronide.  Furthermore,  for  the  ﬁrst  time  in  human  urine a  third
DON-glucuronide  was  detected  and  the  fate  of ingested  masked  DON  forms  (3-acetyl-DON  and  DON-3-lucuronide glucoside)  was  preliminary  assessed.  The  mean  excretion  rate  of ZEN  was determined  to  be  9.4%.  ZEN
was  mainly  present  in its glucuronide  form  and  in  some  samples  ZEN-14-glucuronide  was  directly  deter-hase II metabolismoxicokinetics mined  3–10  h  after  exposure.  For  the  ﬁrst  time  concrete  ﬁgures  have  become  available  for  the  excretion
pattern  of DON  and  ZEN-glucuronides  throughout  a  day,  the comparison  of  total  DON  in 24 h  and  ﬁrst
morning  urine  samples  and  the  urinary  excretion  rate  of total  ZEN  in  humans  following  exposure  through
naturally  contaminated  food.  Therefore,  valuable  preliminary  information  has  been  obtained  through  the
chosen experimental  approach  although  the  study  involved  only  one  single  individual  and  needs  to be
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conﬁrmed  in larger  monitoring  studies.  The  presented  experiment  contributes  to  a better  understanding
of human  DON  and  ZEN in  vivo  metabolism  and  thereby  supports  advanced  exposure  and  risk assessment
to increase  food  safety  and  examine  the  relationship  between  these  mycotoxins  and potentially  associated
chronic  diseases  in the  future.
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. Introduction
The mycotoxins deoxynivalenol (DON, vomitoxin) and zear-
lenone (ZEN) are frequent contaminants of grains and cereal
roducts thus representing an important threat to food safety
CAST, 2003). Produced by various Fusarium species predomi-
antly pre harvest, they occur worldwide. Hence, dietary exposure
hrough the consumption of contaminated food is frequent in
any populations. The trichothecene DON inhibits protein synthe-
is and modulates immune responses resulting in acute toxicity
ith symptoms including vomiting, nausea and diarrhea in humans
hile chronic effects still remain unclear. Toxicological effects and
iseases associated with DON exposure were reviewed recently
Pestka, 2010a,b; Turner et al., 2012). However, epidemiological
tudies are required to critically investigate a potential relation-
hip between the consumption of high DON quantities and the
ncidence of gastroenteritis and potential chronic diseases (Pestka,
010a). Zearalenone (ZEN) and its metabolites exhibit potent estro-
enic activity, hence it is often referred to as a mycoestrogen. ZEN
s implicated in reproductive disorders of farm animals and occa-
ionally in hypoestrogenic syndromes in humans (Zinedine et al.,
007). In addition, it is suspected as a triggering factor for central
recocious puberty development in girls (Massart et al., 2008).
Due to their toxic potential, regulatory limits were introduced
or both mycotoxins in many countries, including the European
nion enforcing the most rigorous policy (European Commission,
006). In addition, detailed risk assessments for DON as well as
or ZEN were carried out by the Joint FAO/WHO Expert Commit-
ee on Food Additives (JECFA) resulting in a provisional maximum
olerable daily intake (PMTDI) of 1.0 g DON and 0.5 g ZEN
er kg bodyweight (FAO/WHO, 2000, 2001). In 2010, the JECFA
pdated its evaluation for DON and concluded to include its
cetylated forms 3-acetyl-deoxynivalenol (3ADON) and 15-acetyl-
eoxynivalenol (15ADON) to deﬁne the proposed value as a group
MTDI (FAO/WHO, 2010). Due to lack of data DON-3-glucoside
DON-3-Glc) was not included in this calculation so far, although
ecent studies in rats and in vitro indicated the possibility that these
lant metabolites might be hydrolysed to the precursor toxin in
umans, contributing to overall toxicity (Berthiller et al., 2011; Nagl
t al., 2012). The European Scientiﬁc Committee on Food (SCF) per-
ormed a risk assessment on ZEN and concluded a temporary TDI of
.2 g/kg bodyweight (SCF, 2000). These TDI values have been an
mportant basis for the current mycotoxin legislation established
n the European Union which are designed to protect consumers to
xceed the TDI.
Human DON and ZEN metabolism was rarely investigated in
he past, mainly due to very low concentrations that occur in bio-
ogical ﬂuids following exposure via contaminated food. Extensive
tudies on the excretion proﬁles of DON in different animal species
ere conducted in the 1980’s. They revealed the ubiquitous for-
ation of DON-glucuronides (DON-GlcA) by indirect methods and
 signiﬁcant difference in urinary excretion and glucuronidation
etween species (Côté et al., 1986; Lake et al., 1987; Prelusky
t al., 1986). This species dependent variation was recently con-
rmed by an in vitro study investigating the hepatic metabolism
f human and six animal liver microsome mixtures (Maul et al.,
012). However, the ﬁrst investigation of the human DON excre-
ion pattern was performed in 2003, when total DON was  proposedichael Sulyok. Published by Elsevier Ireland Ltd. 
as a biomarker of exposure in urine after enzymatic hydrolysis
using -glucuronidase (Meky et al., 2003). The developed indirect
method was applied in various DON exposure studies (reviewed
by Turner, 2010 and Turner et al., 2012) and additionally used
to examine urinary metabolite proﬁles in 34 UK adults (Turner
et al., 2011). Urine samples previously analyzed for total DON
after enzymatic hydrolysis were re-measured without this treat-
ment to indirectly determine the amount of DON-glucuronide to
be approximately 91% (range 85–98%) of total DON. Furthermore,
total urinary DON (sum of free DON + DON-GlcA) was validated as
a biomarker of exposure with an average urinary excretion rate
of 72% (Turner et al., 2010). Recently, our group established an
LC–MS/MS based method to directly quantify DON-GlcA in human
urine using a chemically synthesized, NMR  conﬁrmed DON-3-
glucuronide (DON-3-GlcA) reference standard (Warth et al., 2011).
Within the course of a pilot study to investigate DON exposure
toward Austrian adults, we detected a second DON-glucuronide,
which was  tentatively identiﬁed as DON-15-GlcA. These results
were opposed to a previous work, which only could detect one
DON-glucuronide in human urine by MS/MS experiments, which
were based on theoretical masses (Lattanzio et al., 2011). In the
Austrian study, the newly identiﬁed metabolite DON-15-GlcA was
shown to be the predominant conjugate, accounting for approxi-
mately 75% of total DON-glucuronide. The average glucuronidation
rate was determined to be 86% (range 79–95%) (Warth et al.,
2012a). Fecal excretion of DON, mainly as its detoxiﬁed metabolite
deepoxy-DON, was reported in cow, sheep, pig and rat (Côté et al.,
1986; Prelusky et al., 1986; Eriksen et al., 2003; Nagl et al., 2012)
in varying importance but not investigated in humans so far to the
best of our knowledge. However, due to an average urinary excre-
tion rate of 72% (Turner et al., 2010) it can be derived that excretion
via feces is not the main route in humans. Two  recent in vitro studies
examined the metabolism of DON and its plant metabolite DON-
3-Glc by the human fecal microbiota and found that DON can be
released from its glycosylated form (Dall’Erta et al., 2013; Gratz
et al., 2013).
Zearalenone metabolism was studied in various animals, espe-
cially in pigs as they are particularly sensitive to associated adverse
effects such as decreased fertility. Biotransformation takes place in
two major pathways: Hydroxylation forms the phase-I-metabolites
-zearalenol (-ZEL) and -zearalenol (-ZEL), while conjugation
of ZEN and its reduced forms with glucuronic acid and sulfate
leads to the formation of typical phase-II-conjugation products.
This was  recently also conﬁrmed in Caco-2 cells, which represent
a widely accepted in vitro system for human intestinal absorption
and metabolism (Pfeiffer et al., 2011). Comprehensive reviews were
published by the JECFA committee (FAO/WHO, 2001) and by Met-
zler et al. (Metzler et al., 2010). In the latter, the authors point at
the lack of pharmacokinetic data of ZEN in humans. Knowledge on
zearalenone in vivo metabolism is based on a single experiment
from 1981, where the metabolite pattern in 24 h urine was ana-
lyzed following ingestion of 100 mg  ZEN at once by a male volunteer
(Mirocha et al., 1981). Zearalenone-glucuronide (ZEN-GlcA) and -
ZEL-GlcA were the main metabolites, besides a minor amount of
Open access under CC BY license.-ZEL-GlcA was excreted. All analytes were determined after enzy-
matic hydrolysis and neither free nor sulfated metabolites were
detected. Using the concentrations of the urinary metabolites, it can
be estimated that about 10–20% of the ZEN dose, was recovered in
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gig. 1. Scheme illustrating the experimental setup and sampling strategy. On days
orning void (which was  attributed to the previous day) at 7 am.  Starting on day 
ombining them to 24 h urine samples.
he 24 h urine (Metzler et al., 2010). A study analyzing urine sam-
les obtained from 163 US girls also detected predominantly ZEN
nd -ZEL. However, only free metabolites were quantiﬁed as no
nzymatic hydrolysis was performed (Bandera et al., 2011). Recent
n vitro studies demonstrate that ZEN, together with its metabo-
ites is glucuronidated in humans and animals in the intestine,
iver, and other organs, preferably at the sterically unhindered 14-
ydroxyl group (Pfeiffer et al., 2010). This result in the formation
f e.g. ZEN-14-glucuronide (ZEN-14-GlcA), a metabolite that was
ery recently quantiﬁed in naturally contaminated human urine
amples from Cameroon (Warth et al., 2012b) and South Africa
Shephard et al., 2012). The fecal excretion of ZEN and its metabo-
ites was not examined in humans yet. This elimination route was
ound to be a minor one in pig (Dänicke et al., 2005) while in
at it was reported to be the predominant one (Fitzpatrick et al.,
988).
This experiment was designed to provide tentative information
bout the human in vivo metabolism of the major Fusarium toxins
eoxynivalenol and zearalenone studied in a single individual by
sing a modern multi-biomarker LC–MS/MS method. Special focus
as given to the estimation of urinary excretion rates and the direct
etermination of major conjugation products.
. Materials and methods
.1. Reagents and chemicals
Methanol (LC gradient grade) and glacial acetic acid (p.a.) were pur-
hased from Merck (Darmstadt, Germany), acetonitrile (ACN, LC gradient grade)
rom VWR  (Leuven, Belgium), creatinine from Sigma (Schnelldorf, Germany).
eoxynivalenol-3-O-glucuronide and zearalenone-14-O-glucuronide were synthe-
ized by optimized procedures as described elsewhere (Fruhmann et al., 2012;
ikula et al., 2012). Other standards were purchased from Sigma (ZEN, - and -ZEL)nd Romer Labs Diagnostic GmbH Tulln, Austria (DON, 13C15-DON, deepoxy-DON,
ivalenol, T-2 toxin, HT-2 toxin, ochratoxin A, aﬂatoxin M1, fumonisins B1 and B2).
olid standard substances were dissolved in pure methanol (DON-3-GlcA, nivalenol)
r ACN (DON, ZEN-14-GlcA, ZEN, - and -ZEL). All other standards were delivered
n ACN or ACN/H2O (fumonisins B1 and B2) and stored at −20 ◦C.
able 1
verview of contamination level, daily intake and time point of exposure of the food item
lucoside and 15-acetyl-deoxynivalenol were screened for but not detected in any food s
Food Time of
consumption
Daily intake
(days 3–6; in g)
Mycotoxin contam
DON DON-3-
Breakfast cereals 7–8 am 100 195 4 
Wheat  bran 7–8 am 28 432 4 
Maize  porridge 12:30–1 pm 97 314 16 
Maize  ﬂour 12:30–1 pm 40 465 72 
Bread  8–9 pm 100 49 n.d. 
Wheat  beer 8–9 pm 500 84 3 
Popcorn 9–10 pm 28 371 5 
  Intake (g/d) 138 7  2 only 24 h urine was  collected. The 24 h sampling interval started after the ﬁrst
ingle spot urine samples (n = 45) were collected and analyzed separately and after
A combined multi standard working solution for preparation of calibrants and
spiking experiments was  prepared in ACN containing 10.0 mg/L DON, DON-3-GlcA,
deepoxy-DON, nivalenol and HT-2, 5.0 mg/L fumonisin B1 and B2, 2.5 mg/L ZEN-14-
GlcA, -ZEL, -ZEL and T-2, 1.0 mg/L ZEN and 13C15-DON and 0.125 mg/L aﬂatoxin
M1 and ochratoxin A. DON-15-GlcA was separated and subsequently fractionated
from a highly contaminated human urine sample which contained both, DON-3-
GlcA and DON-15-GlcA (Warth et al., 2012a). Sulfate conjugates were not included
in  the study due to a lack of reference standard (DON-sulfate) and poor chromato-
graphic behavior on the used chromatographic column (ZEN-sulfate).
Enzymatic hydrolysis of the samples was done using -glucuronidase from
Escherichia coli (Type IX-A, Sigma). 500 L urine were mixed with 500 L PBS buffer
(75  mM,  pH 7.4) containing 3000 units of -glucuronidase and incubated at 37 ◦C
for  18 h. Digested samples were centrifuged and 200 L of the supernatant was
diluted with 800 L dilution solvent to result in a total dilution factor of ten like the
untreated samples.
2.2. Study design
The study was conducted on a 27 year old, healthy male volunteer who con-
sumed a special diet over a period of eight days as displayed in Fig. 1. On the ﬁrst and
the  last two  days the person ingested a mycotoxin reduced diet, which was based on
rice, vegetables, fruits and milk products to reach Fusarium mycotoxin blank levels
in  excreted urine. During the four days in between, a diet naturally contaminated
with high levels of DON was consumed, with exactly the same servings each day
at  the same times. This DON intervention diet consisted of cereals with wheat bran
for  breakfast, maize porridge (including maize ﬂour) for lunch and bread, beer and
pop-corn in the evening. Priority was given to a consistent DON  intake during the
day.  As the majority of consumed food items were derived from cereals, the per-
centage of carbohydrates in the overall diet was exceptionally high. The time of
consumption, ingested daily quantities and concentrations of major mycotoxins are
reported in Table 1. In addition, the total quantity of mycotoxins ingested during a
day  of intervention is stated. Vegetables, fruits and drinks (predominantly water)
which are usually not likely to be contaminated with mycotoxins were consumed
ad libitum. Food items consumed during the intervention diet as well as during the
cereal reduced diet (rice) were analyzed for their mycotoxin contamination level
prior consumption.
2.3. SamplesUrine samples were collected as 24 h urine throughout the study, for which on
average 7.5 spot urine samples were combined. A 24 h period lasted from 7 am to 7
am  on the next day to include the ﬁrst morning urine in the sample of the previous
day. The rationale was based on an experiment which revealed that ﬁrst morning
void is well suited to represent exposure of the prior day (Turner et al., 2009). In
s consumed during the high cereal intervention diet (days 3–6). Zearalenone-14-
ample.
ination level (g/kg)
Glc 3ADON ZEN NIV FB1 FB2 T2 HT2
n.d. 4 3 n.d. n.d. n.d. n.d.
n.d. 1 39 n.d. n.d. n.d. n.d.
11 36 17 68 14 15 14
28 148 15 263 135 n.d. n.d.
3 1 3 n.d. n.d. n.d. n.d.
35 n.d. n.d. n.d. n.d. n.d. n.d.
n.d. 2 n.d. 8 n.d. n.d. n.d.
20 10 4 17 7 1.4 1.4
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Table 2
Overview of daily mycotoxin intake and relationship to the established levels of tolerable daily intake.
DON DON-3-Glu 3ADON ZEN NIV FB1 FB2 T2 HT2
 Daily intake (g) 138 7 20 10 4 17 7 1 1
Intake per kg bodyweight (60 kg) 2.3 0.1 0.3 0.2 0.1 0.3 0.1 0.0 0.0
Tolerable daily intake (g/kg bw/d) 1.0a – 1.0a 0.2 0.7 2.0b 2.0b 0.06c 0.06c
Relation to TDI (%) 230 n.d. 34 83 10 15 6 40 39
 acety
a
i
i
ﬁ
b
V
o
a
T
r
w
2
r
T
a
z
r
t
v
w
A
a
s
E
ﬂ
f
u
[
4
G
r
a
o
c
t
(
t
e
a
6
3
7
T
Ra The WHO  updated its deoxynivalenol TDI value 2010 to a group TDI of DON and
b Group TDI for FB1 + FB2 + FB3.
c Group TDI for T2 + HT2.
ddition, an aliquot of each spot urine sample was taken starting on day three to
nvestigate the kinetics of DON/ZEN metabolism and excretion and to investigate
f sampling of ﬁrst morning void is feasible. No spot samples were collected on the
rst  two  days, as they were designed to reach blank samples only. Samples were
rought to the laboratory in the morning and frozen immediately at −20 ◦C.
Cereal based food samples (n = 23) were purchased from supermarkets in
ienna and analyzed on their mycotoxin contamination levels using the method
f  Sulyok et al. (Sulyok et al., 2007). Samples with relatively high deoxynivalenol
nd zearalenone concentrations were chosen to create a reasonable diet plan (see
ables 1 and 2). However, none of the samples exceeded the regulatory limits cur-
ently enforced in the European Union (European Commission, 2006). This study
as  permitted by the ethics commission of the government of Lower Austria.
.4. LC–MS/MS method
Determination of urinary mycotoxins and metabolites was  carried out using a
ecently developed and validated multi-biomarker method (Warth et al., 2012b).
his  method does not require any sample preparation other than centrifugation
nd dilution and enables to directly quantify glucuronides of deoxynivalenol and
earalenone in human urine besides their parent toxins as well as ten other
elevant mycotoxins or metabolites. Brieﬂy, samples were allowed to reach room
emperature, centrifuged for 3 min  at 5600 × g and diluted 1:10 with dilution sol-
ent (ACN/H2O: 10/90). Five L of the diluted sample (corresponding to 0.5 L urine)
ere injected to a 5500 Q-Trap system (AB Sciex, Foster City, CA) equipped with an
gilent 1290 UHPLC system (Waldbronn, Germany). Analytes were separated on
n Atlantis T3 column (3.0 × 150 mm,  Waters, Wexford, Ireland) with 3 m particle
ize and a C18 pre-column. Gradient elution at 35 ◦C was performed within 18 min.
luent A (water) and eluent B (ACN) were acidiﬁed with 0.1% acetic acid and the
ow rate was set to 600 L/min.
ESI-MS/MS was performed in selected reaction monitoring (SRM) mode
or all analytes investigated in this study. The following transitions were
sed as quantiﬁer/qualiﬁer ions: 355.1 [M+Ac]− → 265.2/59.2 (DON), 471.0
M−H]− → 265.2/175.2/441.0 (DON-GlcA), 317.1 [M-H]− → 175.0/131.1 (ZEN),
93.0 [M-H]− → 131.0/175.0 (ZEN-14-GlcA). Apparent recoveries for DON, DON-3-
lcA, ZEN and ZEN-14-GlcA in urine were determined to be 88, 104, 88 and 102%,
espectively (Warth et al., 2012b). As no reference standard is commercially avail-
ble for DON-15-GlcA, we used the apparent recovery of DON-3-GlcA for correction
f results. Furthermore, concentrations of DON-15-GlcA were calculated using the
alibration function of DON-3-GlcA and corrected by its relative MS  response (fac-
or  1.88) as successfully demonstrated in Warth et al., 2012a. Limit of detection
LOD) values were calculated from chromatograms of spiked urine based on a signal
o noise ratio of 3:1 and limits of quantiﬁcation (LOQ) were deﬁned as the low-
st  reference standard which was reproduced with a RSD below 20%. Resulting LOD
nd LOQ values were determined as follows: DON 4 and 6 g L−1, DON-3-GlcA 4 and
 g L−1, DON-15-GlcA 2 and 3 g L−1, ZEN 0.2 and 0.3 g L−1 and ZEN-14-GlcA 2 and
 g L−1. The analytes eluted after 6.6 min  (DON-3-GlcA), 6.7 min  (DON-15-GlcA),
.0  min  (DON), 13.0 min  (ZEN-14-GlcA) and 14.2 min  (ZEN). For determination of
able 3
esults reporting concentrations of deoxynivalenol and its glucuronides determined in 2
DON intakea
(g/d)
DON (g/L) DON-3-GlcAb
(g/L)
DON-15-GlcAb
(g/L)

(
Day 1 – <LOD <LOD 3 3 
Day  2 – <LOD <LOD <LOD n.
Day  3 138 8 9 21 38
Day  4 138 10 7 18 35
Day  5 138 11 8 25 45
Day  6 138 9 7 23 39
Day  7 – <LOD <LOD 5 5 
Day  8 – <LOD <LOD <LOD n.
Averagec 138 9 8 22 39
a No masked forms included.
b Expressed as DON equivalents.
c Days 3–6 (high cereal intervention diet).lated forms.
creatinine concentrations, the samples were diluted 1:10.000 with dilution solvent
and  analyzed by LC–MS/MS as described in Warth et al., 2012a.
External calibration (1/x weighted) was used for quantiﬁcation using the Ana-
lyst  software and results were corrected for dilution and apparent recovery. Two QC
samples were included in each batch of 20 samples within an LC–MS/MS measure-
ment sequence. One was  pooled blank urine while the other was blank urine spiked
with multi standard solution diluted 1:200. The results of the standard QC sample
required to be within 15% of its nominal values, otherwise the whole sequence was
rejected for the affected analyte.
3. Results and discussion
3.1. Human deoxynivalenol metabolism
Results illustrating the excretion of DON and its glucuronides
are displayed in Table 3. As suggested by the literature (Meky et al.,
2003; Turner et al., 2009), the urine reached blank level on day two
due to the cereal reduced diet (days 1–2), with all relevant analytes
below the limit of detection.
During the four days of intervention diet (days 3–6) the
urinary concentrations for DON (8–11 g/L; 16–26 g/d), DON-
3-GlcA (11–15 g/L; 29–32 g/d) and DON-15-GlcA (29–41 g/L;
73–91 g/d) were fairly similar, indicating a comparable interday
metabolism. The total amount of excreted DON  was  calculated as
total DON equivalents to compensate for the higher molar mass
of the glucuronides as done previously (Warth et al., 2012a). On
average 94 g DON equivalents were excreted each day what cor-
responds to a daily excretion rate of 68%. This is in agreement
with Turner et al. (2010) who  determined this rate to be 72% in
35 UK adults independent of sex, age, weight or DON  intake. How-
ever, the value in the UK survey was  based on ﬁrst morning urine
samples and an estimation of DON excreted in 24 h (Turner et al.,
2010). The excretion rate was somewhat lower on the ﬁrst day
of intervention (day 3; 60%) compared to the other days (days
4–6; ø71%) what might be attributed to the diet shift on day
three.Following the shift to cereal reduced diet (day 7), only minor
quantities of the main conjugate DON-15-GlcA were recovered,
while DON and DON-3-GlcA were below their respective detec-
tion limits. This conﬁrms the previously described fast metabolism
4 h urine samples as well as the urinary excretion and glucuronidation rate.
 Total DONb
g/L)
Urine
excretion (L)
 Total DON
excreted (g/d)
Excretion
rate (%)
Conjugation
rate (%)
2.20 6 n.d. n.d.
d. 1.80 n.d. n.d. n.d.
 2.17 82 60 80
 2.73 96 69 72
 2.25 101 73 75
 2.54 98 71 77
2.42 11 n.d. n.d.
d. 1.56 n.d. n.d. n.d.
 2.42 94 68 76
92 B. Warth et al. / Toxicology Letters 220 (2013) 88– 94
Fig. 2. Chronological sequence of DON-GlcA excretion between days 3 and 8 following spot urine analysis (n = 45). DON-15-GlcA ( ) is the main conjugation product at all
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campling points whereas the ratio with DON-3-GlcA () is rather stable. Horizont
rst  morning void (depicted by an arrow) is not always the most concentrated ur
etermined in some spot samples approximately 3–10 h after ingestion.
f deoxynivalenol in humans with no biomarker detectable after
4 h (see also Fig. 3) and veriﬁes the complete absence of any DON
etabolite 21.5 h after the last dietary exposure. The volume of
aily excreted urine was quite variable (1.56–2.73 L/d) although
he daily routine of the volunteer was very similar. This suggests to
ecord the amount of urine in future 24 h surveys as carried out in
he presented study.
When comparing 24 h urine samples with ﬁrst morning urine
amples within the course of this experiment, it became obvi-
us that the ﬁrst void contains higher concentrations of DON
nd metabolites (average DON equivalents 77 g/L) than 24 h
rine (average DON equivalents 39 g/L) as expected. The con-
entration in ﬁrst morning void was approximately a factor two
igher compared to 24 h urine, an observation that needs to be
ecognized in future exposure studies measuring ﬁrst morning
amples. However, this can be overcome by adjusting for creati-
ine content, resulting in less varying concentrations (41 g/g vs.
9 g/g). This is also reﬂected in Fig. 2, illustrating the chronological
haracteristics of DON-GlcA excretion. Maximum concentrations
ere typically determined for ﬁrst morning and afternoon sam-
les. The highly contaminated samples obtained in the afternoon
ours, were typically excreted about 3–5 h after consumption of
unch (maize porridge; accounting for about 36% of daily DON
ntake).
.2. Deoxynivalenol glucuronidation
The mean glucuronidation rate during the intervention diet was
etermined to be 76%, ranging from 72 to 80%. This is in line with
esults obtained in the UK comparing urinary DON concentrations
efore and after -glucuronidase hydrolysis (n = 11; mean 91%,
ange 85–98%; Turner et al., 2011) and in a recent Austrian pilot
urvey applying the same biomarker method used in this experi-
ent (n = 27; mean 86%, range 79–95%, Warth et al., 2012a). The
lightly lower percentage might be in part explained by the higher
ON exposure in this study.
When investigating the rate of different glucuronides, the iso-
er  tentatively identiﬁed as DON-15-GlcA accounted for 73% of
otal DON-glucuronides (range 69–76%). DON-3-GlcA was the con-
ugate with lower amounts detected (mean 27%, range 24–31%)
hich is in excellent agreement with Warth et al. (2012a),
here the ratio of DON-15-Glc/DON-3-GlcA was determined to be
pproximately 3/1. The proportion of DON-GlcAs/total DON and
ON-15-GlcA/DON-3-GlcA was quite stable not only when com-
aring the 24 h urine, but also when looking at the 45 spot samples
ollected during days 3–8 (see Fig. 2).s indicate the average concentrations of the respective glucuronide. Interestingly,
epicted by an arrow with time statement). Zearalenone-14-glucuronide ( ) was
Besides the two described conjugates, a recent in vitro study
detected a third DON-GlcA in liver microsomes of rat, bovine, carp,
trout and partially in man. This conjugate was  assumed to be
DON-7-GlcA as the only additional functional group of the DON
molecule is the hydroxyl group in position C-7 (Maul et al., 2012).
The MS  fragment spectrum showed large similarities to the spec-
tra of the other DON-GlcA’s and its absence after -glucuronidase
treatment conﬁrmed the molecule to be a glucuronide. It eluted
about 0.5 min  after the authentic DON-3-GlcA standard (Maul
et al., 2012). However, another very recent publication conﬁrmed
the structure of a third DON-GlcA to be DON-8-GlcA based on
NMR  experiments (Uhlig et al., 2013). In the course of the pre-
sented study minor amounts of a third DON-glucuronide could
be identiﬁed based on MS/MS  experiments in some highly con-
taminated samples at 7.1 min. Therefore, this is the ﬁrst ﬁnding
of this conjugate in naturally contaminated human urine samples
although it could not be quantiﬁed due to a lack of reference stan-
dard.
3.3. Metabolism of conjugated deoxynivalenol forms (DON-3-Glc
and 3ADON)
During the last decade there is increasing interest and concern
on so called masked mycotoxins, plant metabolites of the parent
mycotoxins. Several studies described the potential to threat con-
sumer safety from these masked forms, in particular the possible
hydrolysis resulting in the release of their toxic parents during
mammalian digestion raises concerns (Berthiller et al., 2013). In this
context the main focus for DON lies on deoxynivalenol-glucoside
(DON-3-Glc). 3-acetyl-deoxynivalenol (3ADON) is a fungal conju-
gate of DON which is a naturally occurring mycotoxin and precursor
of DON formation. During the intervention diet both conjugated
forms were ingested at low quantities (DON-3-Glc: 7 g/d, 3ADON:
20 g/d). This relates to 5 g/d DON from DON-3-Glc and 17 g/d
DON from 3ADON, when taking the different molecular weights
into account. Hence masked forms contributed to approximately
14% of total daily DON intake (22 g of 160 g (138 g +22 g)).
When re-calculating the daily excretion rate taking masked forms
into account, the rate decreases from 68% (see above) to 59% assum-
ing a complete conversion to DON in the gastrointestinal tract.
To investigate whether or not the masked forms are excreted in
human urine unaltered DON-3-Glc and 3ADON were monitored as
well in all 24 h and spot urine samples. 24 h samples were addition-
ally analyzed after enzymatic hydrolysis. In none of the analyzed
samples any masked form was  detected. This might indicate its
hydrolysis to free DON in the body as suggested in pigs for 3ADON
B. Warth et al. / Toxicology Le
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sig. 3. Concentrations of total deoxynivalenol and total zearalenone in 24 h urine
amples following enzymatic hydrolysis. Dashed lines indicate results correlated to
he creatinine content of a sample.
Eriksen et al., 2003) and partially for DON-3-Glc in rats (Nagl et al.,
012). This could also be due to the low dose ingested and the low
ensitivity of the method with estimated LOD values of 0.5 g/L and
.0 g/L for DON-3-Glc and 3ADON, respectively. However, given
he 3ADON intake of 20 g/d, a mean urine volume of 2.42 L/d and
ssuming the excretion rate of DON (72%), approximately 6 g/L
hould be recovered in urine, a concentration that should indeed be
etectable. The same applies for DON-3-Glc (calculated concentra-
ion ca. 2 g/L using the same assumptions). Another reason could
e a low bioavailability and subsequent excretion of conjugated
orms via feces as recently indicated for rat (Nagl et al., 2012).
.4. Human zearalenone metabolism
A quantity of 10 g zearalenone was ingested each day of
ntervention. The great majority (94%) originated from the maize
orridge which was consumed for lunch (12:30–1:00 pm). Due to
he more complex metabolism of zearalenone resulting in vari-
us degradation and conjugation products and limited sensitivity
f the applied method toward its main urinary excretion prod-
ct ZEN-14-GlcA, it was  not possible to evaluate ZEN metabolism
irectly as in the case of DON. Therefore, 24 h urine samples were
nzymatically hydrolysed to measure free ZEN and ZEN-GlcA com-
ined as total ZEN to reach detectable concentrations. During the
ntervention diet, the 24 h urine samples contained on average
.39 g/L total ZEN (range 0.30–0.59 g/L) as reported in Fig. 3.
his corresponds to a daily excretion of 0.94 g and a rate of 9.4%
range 7.0–13.2%), when taking the urine volume (mean 2.42 L) into
ccount. This is in the same range as in the experiment of Mirocha
nd coworkers (1981) where the total ZEN intake was 10.000 times
igher (100 mg), whereof approximately 10–20% were recovered in
he 24 h urine (Metzler et al., 2010). However, in this single exper-
ment ZEN was not ingested via naturally contaminated food and
n an unrealistic high concentration.
ZEN-14-GlcA was directly determined in some spot urine sam-
les 3–10 h after lunch on days 3, 5 and 6 (see Fig. 2). This indicates
apid formation and excretion of ZEN-14-GlcA. Interestingly, it was
ever found in ﬁrst morning samples. The quantity of ZEN ingested
n this study corresponds to a dose slightly below the TDI of the
CF (83%, conﬁrm Table 2). Hence, it can be concluded that it is
ikely to determine ZEN-14-GlcA in case of TDI exceedance using
ur method. For conﬁrmation and more precise estimates of ZEN
xposure, it is recommended to hydrolyse suspected samples to
e-measure for total free ZEN.
.5. Determination of other mycotoxin biomarkersBecause the employed multi-biomarker method is also capa-
le to detect biomarkers of other mycotoxins, all samples were
creened for those was well. However, as expected based on thetters 220 (2013) 88– 94 93
experience that the method is suitable to detect moderate to high
exposures but not the very low background concentrations of
nivalenol (4 g/d), T2/HT2 (2.8 g/d) or fumonisins (total 24 g/d)
ingested within this study, non of the other analytes was  detectable
by means of the applied multi-biomarker method (Warth et al.,
2012b).
4. Conclusions
This is the ﬁrst in vivo case study providing detailed informa-
tion about the human metabolism of DON and ZEN over a period of
eight days using a multi-biomarker LC–MS/MS method. Valuable
information has been gained from one single individual, through
the chosen experimental approach. Thus, for the ﬁrst time concrete
ﬁgures have become available for the excretion pattern of DON and
ZEN-glucuronides throughout a day, the comparison of total DON
in 24 h and ﬁrst morning urine samples and the urinary excretion
rate of total ZEN in humans following exposure through naturally
contaminated food. Furthermore, for the ﬁrst time in human urine,
a third DON-glucuronide was detected and the fate of ingested
masked DON forms (3-acetyl-DON and DON-3-glucoside) was pre-
liminary investigated. However, it has to be pointed out that the
obtained data are not necessarily valid in general due to natural
inter-individual variations. Therefore, this experiment needs to be
extended to a larger group of individuals to investigate these varia-
tions and in particular to validate total urinary ZEN as a biomarker
of ZEN exposure by establishing a dose-response relationship.
The gained knowledge will serve in exposure assessment sur-
veys using biomarkers of exposure to estimate DON and ZEN intake
more accurately in human individuals and populations. In addi-
tion, advanced risk assessment and a more speciﬁc investigation of
a potential relationship between these mycotoxins and associated
chronic diseases are facilitated by this work.
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